Press Releases

Fusion Pharma to Present at the EANM 2018 Congress and BIO Investor Forum 2018

BOSTON, MA and HAMILTON, ONTARIO, October 15, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), will present at two separate conferences this week.

 

On Tuesday, October 16, 2018, Fusion will present scientific data on its lead program FPI-1434 at the European Association of Nuclear Medicine (EANM) 2018 Congress.  The meeting is behind held in the CCD, Congress Center Dusseldorf, in Dusseldorf, Germany.

 

On Thursday, October 18, 2018, at 10:00am PT, Fusion will present at the BIO Investor Forum 2018. The event is being held at the Westin St. Francis Hotel in San Francisco, California.

 

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPI-1434 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.  For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
info@fusionpharma.com

Fusion Pharma Announces Formation of Advisory Board

Fusion Pharmaceutical to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018

BOSTON, MA and HAMILTON, ONTARIO, April 27, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), announced it will present at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada. The Fusion team will also participate in one-on-one meetings with industry stakeholders during the conference.

Details of the presentation are as follows:

  • Date: Thursday, May 3, 2018
  • Time: 11:30am ET
  • Location: Hall B, Sheraton Centre Toronto Hotel, Toronto, Canada

 

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest development in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings.


About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.  For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
info@fusionpharma.com

 

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology

Technology will be used to progress Fusion’s pipeline of targeted alpha therapeutics for the treatment of cancers

Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage each other’s strengths in recombinant protein technologies and radiopharmaceutical development. Isogenica is a leader in the design and construction of highly diverse synthetic antibody libraries and the use of novel in vitro polypeptide display systems. Fusion is a biopharmaceutical company focused on developing novel targeted alpha therapeutics, or radiopharmaceuticals, for the treatment of cancers.

Under the terms of the agreement, Isogenica has granted a licence to Fusion to utilise its proprietary in vitro CIS Display technology, for the discovery, development and commercialisation of therapeutic products derived from polypeptide libraries generated using this technology. Fusion will use the Isogenica technology to advance its internally developed drug pipeline. Under the terms of the agreement, Isogenica will receive an upfront fee and annual licence payments. If therapeutic products are advanced into development, Isogenica is entitled to additional milestone payments.

Adam Collier, Isogenica’s Director of Commercial Development commented:This is another very significant deal for Isogenica, which highlights the robustness and utility of the company’s CIS Display technology as an excellent starting point for the rapid and efficient discovery of novel biotherapeutics. We look forward to working closely with Fusion to help their exciting drug discovery strategy to progress.

We are looking forward to the partnership with Isogenica,” said Eric Burak, Fusion’s CSO. “As part of our long-term strategy, Fusion is committed to both identifying our own agents and in-licensing assets that can be transformed into targeted alpha therapeutics. This partnership with Isogenica will help us to advance our internally developed pipeline of drugs while we progress our lead product, FPX-01, into the clinic later this year.”

 

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.

 

About Isogenica Ltd

Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. Partners can access an advanced camelid single-domain antibody library (llamdA™) and state-of-the-art, fully synthetic and highly diverse human Fab antibody libraries (Alexandria™). The company uses its proprietary Colibra™ library technology to ensure that the libraries very accurately reflect its advanced designs. Libraries can be screened in various formats, including phage and CIS Display, a proprietary in vitro display technology which maintains the high diversity of the llamdA™ libraries through the discovery process. CIS Display is also available as a stand-alone polypeptide display technology.

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
info@fusionpharma.com

 

Fusion Pharmaceuticals announces Marc Schwabish, PhD, joins as SVP, Business Development and US Operations 

BOSTON, MA and HAMILTON, ONTARIO, February 21, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has appointed Marc Schwabish, PhD, as Senior Vice President, Business Development and US Operations. Dr. Schwabish will lead a range of activities including licensing, partnering, commercialization, and financing activities.

Dr. Schwabish joins from Bayer AG where he was Head of US Pharma Business Development and Licensing. He has previous work experience at Eisai, other Pharma and Biotech companies, and Wall Street, following completion of a PhD in Biochemistry.

“This year, Fusion is entering the clinic with our lead program, FPX-01, and we are simultaneously executing an aggressive growth plan through in-licensing and partnership agreements,” said John Valliant, PhD, CEO of Fusion.  “Marc’s diverse background and strong BD track record are a perfect match with Fusion’s strategic goals, including the build-out of our US Operations.”

“The vision, technology platform, and rapid progress Fusion has made is extraordinary,” said Dr. Schwabish. “Fusion’s internal discovery and clinical programs and its unique platform technologies enable the company to rapidly develop and evaluate new targeted radiopharmaceuticals. Fusion can use new or existing antibodies – either as a monotherapy or as a combination for a synergistic response. It’s a very exciting time at Fusion and I am honored to join the team.”

 

About Marc Schwabish

Marc Schwabish was most recently Head of US Pharma Business Development and Licensing at Bayer. He worked across Bayer’s therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships.  Prior to Bayer, Marc had both Business Development and Alliance Management responsibilities at Eisai.  His deal experience at Eisai covered a range of diseases and stages of assets — from early research technologies through commercialized therapeutics.  Marc previously worked in Healthcare Investment Banking at RBS (Leverage Finance and M&A), Pharma Strategy Consulting at Leerink Swann (now Navigant), and other Pharma/Biotech companies (R&D and Product Management). He has closed over 25 transactions across Anti-Infectives, Cardiology, GI, Metabolism, Neurology, Oncology, Thrombosis, and Women’s Healthcare. He holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.

 

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.  For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
info@fusionpharma.com

 

Life Sciences Ontario Announces Recipients of 2018 LSO Awards

TORONTO– LSO today announced the recipients of its 2018 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector. The awards will be presented during LSO’s Celebration of Success Awards Dinner at Toronto’s Liberty Grand, February 28, 2018.

The 2018 awardees are as follows:

  • Lifetime Achievement Award: Ilse Treurnicht, Former CEO, MaRS Discovery District
  • Community Service Award: George Mallay, Past General Manager, Sarnia-Lambton Economic Partnership
  • Volunteer Award: Shanna Brisebois, Manager, Health Policy and Stakeholder Relations, Novartis Pharmaceuticals Canada Inc.
  • Life Science Company of the Year: Fusion Pharmaceuticals Inc.

The LSO Awards are an important part of the organization’s mandate to advocate for Ontario’s life sciences sector, by celebrating the individuals and companies behind its success.

“This year’s LSO Award recipients represent an outstanding group of Ontario life sciences innovators who have made an enormous impact on our sector,” says LSO President and CEO Jason Field. “Ontario’s life sciences sector holds the key to our economic and social prosperity – and it is fueled by the contributions of talented and hardworking individuals.”

To register for LSO’s 2018 Celebration of Success Awards Dinner, click here.

To explore sponsorship opportunities, contact: admin@lifesciencesontario.ca

 

 

Biographies

Ilse Treurnicht, Former CEO, MaRS Discovery District

Lifetime Achievement Award

For the past 12 years, Ilse Treurnicht has overseen the development of the MaRS Centre, an innovation hub located in the heart of Toronto’s Discovery District, as well as the launch and growth of MaRS’ broad suite of programs and partnerships. Today, the 1.5-million-sq.-ft. facility offers specialized infrastructure to leading research groups, startups and young scaling firms, multinational businesses and investors – drawing 6,000 people from 150+ organizations to work there every day.

MaRS supports innovators and entrepreneurs building high-impact growth businesses, providing connections to critical talent, capital, and customer networks. In addition, MaRS works with partners to accelerate the adoption and diffusion of innovation in regulated sectors, with a special focus on modernizing procurement, liberating data, and developing outcomes-based funding models in the health sector.

Ilse joined MaRS in 2005 from her role as CEO of Primaxis Technology Ventures, a seed-stage venture fund. She has been a research scientist and entrepreneur, with senior roles in a number of emerging technology companies. She was Chair of the Canadian Task Force on Social Finance in 2010 and served on the Government of Canada’s Science, Technology and Innovation Council (STIC), and is a member of the Advisory Council on Economic Growth. She chairs the board of Triphase Accelerator Corporation, a cancer drug development firm.

Ilse holds a DPhil in chemistry from Oxford University, which she attended as a Rhodes Scholar.

 

George Mallay, Past General Manager, Sarnia-Lambton Economic Partnership

Community Service Award

George Mallay has more than 30 years’ experience in the economic development profession, including strategy, marketing, land and real estate development, venture financing, and entrepreneurship. He helped facilitate thousands of jobs and several billion dollars in new capital investment, and develop high tech/cluster support infrastructure for the Sarnia-Lambton hybrid chemistry cluster and Ottawa technology complex.

George recently retired after 21 years as General Manager of the Sarnia-Lambton Economic Partnership. He played a leading role in establishing the award-winning Western Sarnia-Lambton Research and Development Park. He has also been a Board member of Bioindustrial Innovation Canada since its inception, advocating for development of the hybrid chemistry complex, and was the catalyst behind the Sarnia-Lambton Industrial Alliance.

George is past co-chair of the Bluewater Sustainability Initiative and has served on the Lambton College Foundation Board, Bluewater Technology Access Center, RAIL, and the Sarnia-Lambton Chamber of Commerce. In 2016 he also served as chair of the Ontario Cleantech Alliance. He holds degrees in economic geography and urban planning, as well as an MBA.

 

Shanna Brisebois, Manager, Health Policy and Stakeholder Relations, Novartis Pharmaceuticals Canada Inc.

Volunteer Award

Shanna Brisebois is Manager of Health Policy and Stakeholder Relations at Novartis Pharmaceuticals Canada Inc. In this role, Shanna works with government, industry, and patient groups to strengthen Ontario’s life science ecosystem and ensure patients have access to the medication they need to improve their lives.

Prior to joining Novartis, Shanna led communications at de Souza Institute, a not-for-profit in oncology continuing education. While in government, Shanna held a number of senior positions in the ministries of Health Promotion, Municipal Affairs and Housing and Infrastructure. Shanna also worked as a public affairs consultant at Fleishman-Hillard as an Associate Vice-President representing the health and life sciences sectors.

Shanna is passionate about community engagement and building a strong Ontario. She was part of the team that successfully won the Toronto 2015 Pan Am Games bid. Shanna was also part of the team in Ontario’s recent BIO bid. She is active in the community, sitting on various not-for-profit committees and groups, including United Way’s GenNext.

 

Fusion Pharmaceuticals Inc.

Life Sciences Company of the Year

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, focused on becoming the leader in the targeted alpha therapy field. Fusion, which is a spin out from McMaster University’s Centre for Probe Development and Commercialization (CPDC), exploits its unique expertise in linking medical isotopes to targeting molecules to create highly effective cancer therapeutics. In addition to its lead program, FPX-01, with a clinical trial planned for early 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules and forming new strategic partnerships.

FPX-01 has been designed to deliver and internalize a lethal and highly localized radioactive payload into cancer cells. The precise targeting causes selective and extremely effective destruction of tumor cells at low doses. The recent marketing launch of Xofigo® (radium-223 dichloride), an alpha emitting agent for the treatment of bone metastases associated with mCRPC, has re-invigorated the radiopharmaceutical space and created demand for using alpha therapy for other cancers.

Fusion believes that FPX-01 will benefit from this positive market environment and defined regulatory pathway and, as FPX-01 has the capacity to treat a broad range of hard-to-treat cancers, it also has the potential to achieve significant commercial success.

 

 

ABOUT LIFE SCIENCES ONTARIO (LSO)

Life Sciences Ontario is a member-driven organization that represents and promotes the province’s vibrant and diverse life sciences sector. LSO collaborates with governments, academia, industry, and other life science organizations in Ontario and across Canada to promote and encourage commercial success throughout the sector. Membership in Life Sciences Ontario includes individuals, students, emerging companies, investors, service providers, and companies with marketed products. The organization provides a wide range of networking and educational events, and operates a mentorship program that is helping to develop highly-skilled talent and build new business opportunities for the life sciences sector.LSO is an effective conduit for delivering policy options to governments, and is dedicated to promoting Ontario’s life sciences sector internationally.

 

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
905-525-9140 x26882
info@fusionpharma.com

Life Sciences Ontario
Melissa Hughes
Director, Marketing & Communications
melissa@lifesciencesontario.ca

Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics

HAMILTON, ONTARIO, September 25, 2017Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD. New investors in the second closing include Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc., who join the existing group of international investors, FACIT, Genesys Capital, HealthCap, Johnson & Johnson Innovation – JJDC, Inc., and TPG Biotech.

 

Fusion Pharmaceuticals also announced that Terry Gould of Adams Street Partners and Alan O’Connell of Seroba Life Sciences have joined the company’s board of directors.

 

Targeted alpha-particle emitting radiotherapeutics combine the precision of molecular targeting agents, such as antibodies, with the potency of alpha-particle emitting radioisotopes to specifically attack and eradicate cancer cells. Fusion uses its radiochemistry expertise to convert established and novel targeting molecules into potent alpha therapies.

“We are delighted by the significant interest in Fusion Pharmaceuticals, which is driven by the excitement for our pipeline as well as the precision and potency that can be achieved through targeted delivery of medical isotopes that emit alpha particles,” said John Valliant, Ph.D., Fusion’s Chief Executive Officer. “Fusion will use the additional funds to accelerate the clinical development of our lead program FPX-01, expand our pipeline through in-licensing targeting molecules and form new strategic partnerships.”

 

FPX-01 is an antibody-targeted radiotherapy, which seeks out a specific biomarker of resistance that is present on nearly all types of treatment refractory cancers. The technology is designed to selectively deliver actinium-225 to tumor cells so that in conjunction with internalization, the alpha particles emitted will eradicate diseased tissue.

 

Fusion Pharmaceuticals is a spinout from the Centre for Probe Development and Commercialization (CPDC), which is a  Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. The CPDC, which was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE) and the Ontario Institute for Cancer Research (OICR), has rapidly become a world leader in the development, translation and manufacturing of radiopharmaceuticals.

 

Fusion Pharmaceuticals is also developing centyrin-based alpha therapies against a series of cancer markers. Centyrins are small proteins that are characterized by high selectivity and specificity, combined with tunable pharmaceutical properties and efficient manufacturing. Fusion obtained the candidates through two licensing agreements with Janssen Biotech, Inc. in transactions facilitated by Johnson & Johnson Innovation.

 

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for early 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules and forming new strategic partnerships.  For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.

 

Contacts

Fusion Pharmaceuticals
Lynn Wick
905-525-9140 x26882
info@fusionpharma.com

Media/Investors
Andrew Mastrangelo
LaVoieHealthScience
617.374.8800, ext. 108
amastrangelo@lavoiehealthscience.com

Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments

HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation – JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT (Fight Against Cancer Innovation Trust). Targeted alpha-particle emitting radiotherapeutics combine the precision of molecular targeting agents, such as antibodies with the potency of alpha-particle emitting radioisotopes to specifically attack and eradicate cancer cells.
The syndicate is strengthened by HealthCap’s specialized expertise in pioneering a new wave of successful radiotherapeutic companies, such as Algeta and Nordic Nanovector.
Fusion Pharmaceuticals is a spinout from the Centre for Probe Development and Commercialization (CPDC), an organization that Dr. John Valliant, Ph.D., founded in 2008 and is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. The CPDC, which was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE) and the Ontario Institute for Cancer Research (OICR), has rapidly become a world leader in the development, translation and manufacturing of radiopharmaceuticals.
In addition to Dr. Valliant, founder and chief executive officer, the company’s board of directors consists of Asish Xavier, Ph.D. (Johnson & Johnson Innovation – JJDC, Inc.), Robert Sutherland, Ph.D., Centre for Probe Development and Commercialization (CPDC), Eran Nadav, Ph.D. (TPG Biotech), Johan Christenson, M.D. (HealthCap) and Damian Lamb (Genesys), who will assume the role of chairman of the board.
“Targeted delivery of medical isotopes that emit alpha particles can be used to kill tumor cells with remarkable precision and unprecedented potency, and it has the added potential of having complementary effects with treatments which activate the immune system,” said Dr. John Valliant, CEO. “Fusion is focused on combining our expertise in radiopharmaceutical development and production with the appropriate targeting molecules to create a new generation of therapeutics that can address the need for better cancer treatments. Fusion is proud to join a wave of new Canadian biotech companies that are being launched with innovative technologies emerging from research institutions like McMaster University.”
Fusion Pharmaceuticals will use the financing proceeds to advance its lead program, FPX-01, into human clinical trials. FPX-01 is an antibody-targeted radiotherapy, which seeks out a specific biomarker of resistance that is present on nearly all types of treatment refractory cancers. The technology is designed to selectively deliver actinium-225 to tumor cells so that in conjunction with internalization, the alpha particles emitted will eradicate diseased tissue. In parallel, Fusion Pharmaceuticals gained access to a centyrin-based targeting molecule in preclinical development that has the potential to deliver isotopes to several cancer types and access to the centyrin protein targeting platform in two licensing agreements with Janssen Biotech, Inc. in transactions facilitated by Johnson & Johnson Innovation.
Centyrins are protein targeting agents, proprietary to Janssen Biotech, characterized by high selectivity and specificity, combined with tunable pharmaceutical properties and efficient manufacturing. Fusion Pharmaceuticals is building its pipeline through access to the centyrin platform in combination with proprietary labeling technologies, which can be applied to a wide range of targeting molecules.

Fusion Pharmaceuticals – A Product of a National Centre of Excellence with Comprehensive Sector Expertise

Fusion Pharmaceuticals is a spin out from the Centre for Probe Development and Commercialization (CPDC), which is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University. The CPDC was created to take promising new technologies developed at Universities and use the arising knowledge advantages to realize economic and health benefits for Canadians. The CPDC, which employs over 80 people and has locations and major partnerships in Hamilton, Toronto, Ottawa and Boston, is supported by a range of stakeholders including the Networks of Centres of Excellence, the Ontario Institute for Cancer Research, McMaster University and several industry partners. See www.imagingprobes.ca for additional details.

Innovation Driven and Experienced Management Team

Fusion Pharmaceuticals was founded by Dr. John Valliant, who was also the founder and CEO of CPDC. Under Dr. Valliant’s direction, the CPDC supplied radiopharmaceuticals for over 40 clinical trials, facilitated the creation of three new companies, including building a rapidly expanding manufacturing business. Dr. Valliant, a Canada Research Chair in Medical Isotopes and Molecular Imaging Probes, is a Professor of Chemistry and Chemical Biology at McMaster University. He has won numerous awards including being selected as one of Canada’s top 40 under 40 in 2010.
Fusion’s discovery and development programs are led by the chief scientific officer, Dr. Eric Burak, Ph.D. Eric previously held positions at CPDC, Theracos, Rib-X Pharmaceuticals and Guilford Pharmaceuticals. Eric oversees a world-class team of chemists and biologists who have extensive experience and unique skills in the alpha therapy field.

Alpha Therapies

Certain medical isotopes emit alpha particles, which are highly energetic ions that deposit their energy over very short distances traveling approximately the width of a single cell. When alpha emitting medical isotopes are delivered to cancer cells, they can kill tumor cells through multiple mechanisms including double stranded DNA breaks, which makes repair and hence resistance unlikely. Targeted alpha therapeutics use significantly smaller amounts of material than typical antibody-drug conjugates making it possible to exploit a wider array of drug targets and they do not require complex linkers to release the warhead. One of the additional benefits of Fusion’s alpha therapeutic approach will be creation of a companion diagnostic with each candidate.

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a new pharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01, Fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. Fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.

Contacts
Media/Investors:
Sharon Correia
LaVoieHealthScience
scorreia@lavoiehealthscience.com
617-412-8779
Lynn Wick
Fusion Pharmaceuticals
info@fusionpharma.com
905-525-9140 x26882

FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics

Image-guided medicines for hard to treat cancers built using next generation medical isotopes

TORONTO, ON (December 16, 2015) – FACIT and Fusion Pharmaceuticals (“Fusion”) announced today an investment to support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer. Fusion’s drug candidate leverages the potent cell-killing potential of alpha particle-emitting medical isotopes, with the precise targeting ability of a monoclonal antibody to selectively internalize and destroy cancer cells while sparing neighbouring healthy cells. Early results from a Phase I imaging study demonstrated on-target delivery in patients with solid tumours. FACIT’s investment will support efforts to advance FPX-01 into a Phase I/II clinical trial to examine its potential to treat cancer.

Fusion is leveraging its unique expertise in creating alpha-emitting therapies to build and cultivate a pipeline of novel products through both in-licensing and academic/industrial collaborations. The effectiveness and value of alpha-emitting agents is validated by recent approvals and marketing launches of Bayer’s Xofigo®, which is administered on an out-patient basis. FPX-01 is expected to have the ability to treat a wide range of different tumour types given the high level of expression of the drug’s target in numerous cancers.

Jeff Courtney, FACIT’s Chief Commercial Officer, remarked “Given the re-invigoration of the radiopharmaceutical space, Fusion represents a unique opportunity to leverage the expertise of the Centre for Probe Development and Commercialization in manufacturing radiopharmaceuticals and Fusion’s proprietary chemistry. We believe Fusion’s unique alpha-emitting therapies are positioned well to build on the recent successes in the field and, if proven to be effective in treating cancer, represent an attractive complement to existing and new oncology regimens.”

Fusion is a spin-out from the Centre for Probe Development and Commercialization (“CPDC”) at McMaster University in Hamilton, Ontario. Created in 2008 under the Centres of Excellence for Commercialization and Research (“CECR”) program, CPDC has received funding support from the Ontario Institute for Cancer Research (“OICR”) and additional private and public sector support. The CPDC has grown to become a leader in the clinical development and manufacturing of radioimaging and radiotherapeutics. In 2015, CPDC conducted a clinical trial in which FPX-01 was administered in an imaging study lead by Drs. Rosalyn Juergens and Karen Gulenchyn, at Hamilton Health Sciences.

“Alpha (particle)-emitting agents have the potential to eradicate even the most resistant types of cancers and unlike previous generations of therapeutic radiopharmaceuticals they can be administered in conventional cancer treatment facilities,” said Dr. John Valliant, CEO of Fusion Pharmaceuticals and Professor at McMaster University. “Fusion’s approach has the added benefit that it uses non-invasive imaging to show that the drug hits the target of interest, and as a way to select patients who are most likely to respond to treatment. We are excited to be joined by FACIT to create a new Canadian biotechnology company to advance FPX-01 and build our pipeline of new drug candidates and tools to help deliver effective personalized treatments to cancer patients.”

About FACIT
FACIT (Fight Against Cancer Innovation Trust) is an independent business trust established by the Ontario Institute for Cancer Research (OICR) to undertake development and commercialization activities related to cancer research, products and drug discovery. For more information, please visit the website at facit.ca or email info@facit.ca.

About Fusion Pharmaceuticals
Fusion Pharmaceuticals is a clinical stage company focused on developing novel radiotherapeutics for the treatment of cancer. Fusion is a spin-out from the Centre for Probe Development and Commercialization (CPDC) at McMaster University, Hamilton. Please visit the website at fusionpharma.com.